# Dasatinib Combined With Chemotherapy in Relapsed t(8;21) Acute Myeloid Leukemia With KIT D816 Mutation

> **NCT03560908** · PHASE1 · WITHDRAWN · sponsor: **Institute of Hematology & Blood Diseases Hospital, China**

## Conditions studied

- Relapsed AML
- T(8;21)
- C-KIT Mutation

## Interventions

- **DRUG:** Dasatinib

## Key facts

- **NCT ID:** NCT03560908
- **Lead sponsor:** Institute of Hematology & Blood Diseases Hospital, China
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2018-07-01
- **Primary completion:** 2020-12-31
- **Final completion:** 2021-12-31
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** No enough eligable participants enrolled
- **Last updated:** 2025-05-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03560908

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03560908, "Dasatinib Combined With Chemotherapy in Relapsed t(8;21) Acute Myeloid Leukemia With KIT D816 Mutation". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03560908. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*